Overview

Hestia Insight Inc. (“Hestia” or the “Company”) is a healthcare and biotech-focused company that provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services through its two wholly owned subsidiaries, Hestia Investments Inc. and HSTA HEALTH INC. (d/b/a Hestia Vending).

The Company was previously known as Luxshmi Investments, Inc. until it changed its name to Hestia Insight Inc. in March 2019. In May 2019, Hestia Investments Inc. became a wholly owned subsidiary of the Company through a share exchange transaction.

Hestia Investments provides consulting and advisory services to micro, small and medium-sized companies in the healthcare and biotech sectors. Hestia Vending operates in the healthy food, beverage and wellness products industry, as well as the smart vending machine industry. The Company aims to make strategic acquisitions and enter joint ventures with emerging growth companies in the healthcare and biotech sectors.

Our Markets and Services

Hestia Investments provides strategic consulting, medical supply sales support, management, and capital market advisory services to select micro, small and medium-sized companies in the healthcare and biotech sectors.

Hestia Vending operates in the healthy food, beverage and wellness products industry and the smart vending machine industry. In July 2022, Hestia Vending purchased 10 fully-automated vending machines and related equipment for $98,745 as part of a vending pilot program. In August 2023, the Company sold 8 of these vending machines for $19,000. Hestia Vending also entered a strategic partnership with ChargerGoGo, Inc. to introduce smart phone charging station and power bank kiosks.

Strategic Shift and Capital Raise

During the six-month period, Hestia Insight discontinued its legacy operations in Healthy Vending Services and Portable Charging Network Business to focus on high-growth areas in AI product development and IP-based consulting.

The Board approved a capital raise of up to $5 million through equity and/or convertible debt. The proceeds will support the expansion of the AI development team, R&D acceleration, marketing of AI consulting tools, and general corporate purposes. This strategic shift aligns with the Company’s goal to become a leader in AI-driven advisory services.

Sales and Marketing

Hestia seeks to develop new business through relationships driven by its senior management, who have extensive contacts throughout the healthcare system. The Company’s senior management is seeking opportunities for joint ventures, strategic relationships and acquisitions in the healthcare and biotech sectors.

Business Model

The Company intends to pursue the acquisition and development of healthcare-related technologies in the healthcare and biotech sectors through acquisition, licensing or joint ventures. Hestia will also consider investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.

Competitive Advantages

Hestia focuses on small and micro-cap companies in the healthcare and biotech sectors with limited access to growth capital. The Company provides specialized consulting services to assist these companies with their operations in the public markets. Hestia’s management team is experienced in risk management and exit planning. The Company’s competitive advantages include a global business network of healthcare, investment and financial professionals who are integrated into the technology licensing and commercialization departments of universities and institutions.

Strategic Relationships

Hestia has entered into non-binding agreements with Noether Science and Technologies, Inc. to establish an exclusive partnership focused on research and treatment of neurological and psychiatric disorders, and with Immudyne Nutritional LLC to act as a sales agent for certain of Immudyne’s medical products.

Intellectual Property

Hestia does not own any patents. The Company relies on a combination of copyright, trademark, trade secret, non-disclosure, and contractual safeguards to protect its intellectual property rights.

Competition

In its consulting business, Hestia competes with a number of advisory firms offering similar services, including consulting and strategy firms, market research providers, technology vendors, and specialized advisory service providers. As the Company expands through joint ventures, acquisitions and strategic partnerships, it will face competition from other direct service providers, emerging technologies and medical communication platforms.

Government Regulation

The healthcare industry in the U.S. is highly regulated and subject to changing political, legislative, and regulatory influences. Hestia’s failure to accurately anticipate or comply with these regulations could create liability for the Company and negatively affect its business.

Going Concern

Hestia has a limited operating history, and its continued growth is dependent on generating revenue, obtaining additional financing, and paying liabilities arising from normal business operations. The Company had accumulated deficits of $(735,079) at May 31, 2025, and the report of its independent registered public accounting firm contained an explanatory paragraph regarding its ability to continue as a going concern. Hestia’s ability to continue as a going concern is dependent on its ability to carry out its business plan, achieve profitable operations, and obtain additional working capital.